EE200300045A - Kristalne ravimaine - Google Patents

Kristalne ravimaine

Info

Publication number
EE200300045A
EE200300045A EEP200300045A EEP200300045A EE200300045A EE 200300045 A EE200300045 A EE 200300045A EE P200300045 A EEP200300045 A EE P200300045A EE P200300045 A EEP200300045 A EE P200300045A EE 200300045 A EE200300045 A EE 200300045A
Authority
EE
Estonia
Prior art keywords
drug substance
crystalline drug
crystalline
substance
drug
Prior art date
Application number
EEP200300045A
Other languages
English (en)
Estonian (et)
Inventor
James Harris Laurence
Anthony Storey Richard
Shaw Wood Albert
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200300045A publication Critical patent/EE200300045A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
EEP200300045A 2000-07-28 2001-07-18 Kristalne ravimaine EE200300045A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
EE200300045A true EE200300045A (et) 2004-12-15

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300045A EE200300045A (et) 2000-07-28 2001-07-18 Kristalne ravimaine

Country Status (46)

Country Link
EP (1) EP1305314B1 (es)
JP (1) JP2004505087A (es)
KR (1) KR100457937B1 (es)
CN (1) CN1207297C (es)
AP (1) AP1400A (es)
AR (1) AR032628A1 (es)
AT (1) ATE286901T1 (es)
AU (2) AU2001272690B2 (es)
BG (1) BG107266A (es)
BR (1) BR0112734A (es)
CA (1) CA2417264C (es)
CZ (1) CZ2003126A3 (es)
DE (1) DE60108398T2 (es)
DO (1) DOP2001000217A (es)
DZ (1) DZ3364A1 (es)
EA (1) EA004681B1 (es)
EC (1) ECSP034454A (es)
EE (1) EE200300045A (es)
ES (1) ES2231521T3 (es)
GE (1) GEP20053494B (es)
HK (1) HK1055954A1 (es)
HR (1) HRP20030061A2 (es)
HU (1) HUP0302982A3 (es)
IL (1) IL153226A0 (es)
IN (1) IN2002MU01649A (es)
IS (1) IS6626A (es)
MA (1) MA26931A1 (es)
MX (1) MX233602B (es)
MY (1) MY117831A (es)
NO (1) NO324220B1 (es)
NZ (1) NZ523226A (es)
OA (1) OA12337A (es)
PA (1) PA8523501A1 (es)
PE (1) PE20020277A1 (es)
PH (1) PH12001001922B1 (es)
PL (1) PL365133A1 (es)
PT (1) PT1305314E (es)
SK (1) SK572003A3 (es)
SV (1) SV2001000570A (es)
TN (1) TNSN01112A1 (es)
TW (1) TWI285643B (es)
UA (1) UA72631C2 (es)
UY (1) UY26854A1 (es)
WO (1) WO2002010171A1 (es)
YU (1) YU4703A (es)
ZA (1) ZA200301457B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
GEP20084329B (en) 2003-04-29 2008-03-25 Pfizer Ltd 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
CA2562251C (en) 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
AU2006245416B2 (en) * 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003039T2 (tr) * 1998-04-20 2001-01-22 Pfizer Inc. Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
NZ523226A (en) 2003-07-25
TWI285643B (en) 2007-08-21
WO2002010171A1 (en) 2002-02-07
EP1305314B1 (en) 2005-01-12
DE60108398D1 (de) 2005-02-17
BR0112734A (pt) 2004-08-10
HUP0302982A3 (en) 2005-01-28
PT1305314E (pt) 2005-04-29
PH12001001922B1 (en) 2006-11-21
JP2004505087A (ja) 2004-02-19
UA72631C2 (uk) 2005-03-15
CN1207297C (zh) 2005-06-22
PA8523501A1 (es) 2002-10-24
NO324220B1 (no) 2007-09-10
HRP20030061A2 (en) 2003-04-30
TNSN01112A1 (fr) 2005-11-10
AU2001272690B2 (en) 2005-12-08
CZ2003126A3 (cs) 2004-02-18
CA2417264A1 (en) 2002-02-07
OA12337A (en) 2006-05-15
EA004681B1 (ru) 2004-06-24
SK572003A3 (en) 2004-05-04
ECSP034454A (es) 2003-03-10
NO20030416D0 (no) 2003-01-27
ATE286901T1 (de) 2005-01-15
EA200300079A1 (ru) 2003-06-26
DE60108398T2 (de) 2005-12-22
DZ3364A1 (fr) 2002-02-07
MY117831A (en) 2004-08-30
BG107266A (bg) 2003-07-31
SV2001000570A (es) 2002-09-03
UY26854A1 (es) 2002-02-28
ES2231521T3 (es) 2005-05-16
PL365133A1 (en) 2004-12-27
AP1400A (en) 2005-04-28
MX233602B (es) 2006-01-10
AP2001002234A0 (en) 2001-09-30
AU7269001A (en) 2002-02-13
AR032628A1 (es) 2003-11-19
KR100457937B1 (ko) 2004-11-20
HK1055954A1 (en) 2004-01-30
MA26931A1 (fr) 2004-12-20
HUP0302982A2 (hu) 2003-12-29
KR20030016430A (ko) 2003-02-26
MXPA03000856A (es) 2003-06-06
IL153226A0 (en) 2003-07-06
YU4703A (sh) 2006-01-16
EP1305314A1 (en) 2003-05-02
NO20030416L (no) 2003-02-05
IN2002MU01649A (es) 2004-12-11
PE20020277A1 (es) 2002-05-11
DOP2001000217A (es) 2002-10-30
CN1444585A (zh) 2003-09-24
ZA200301457B (en) 2004-04-28
IS6626A (is) 2002-11-18
CA2417264C (en) 2007-06-12
GEP20053494B (en) 2005-04-25

Similar Documents

Publication Publication Date Title
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
NO20030627L (no) Hydrogel-drevet medikament doseringsform
ATE540013T1 (de) Naphthalinderivate
DK1524266T3 (da) Farmaceutisk sammensætning
ITTO20010008A0 (it) Formulazione farmaceutica
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
DE60115698D1 (de) Medikamentenspender
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
MXPA03001425A (es) Compuestos farmaceuticos.
ATA111299A (de) Schnullersauger
NO20022606L (no) Farmasöytiske kombinasjoner
DE50102752D1 (de) Fungizide wirkstoffkombinationen
NO20014926L (no) Farmasöytiske forbindelser
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
DE10196460T1 (de) Selbstzerstör-Spritze
ID30397A (id) Larutan oral prukaloprida
DK1246791T3 (da) Aminomethyl-phenyl-cyklohexanonderivater
IS6163A (is) Lyfjakomplex
EE200300045A (et) Kristalne ravimaine
DE50002125D1 (de) Fungizide wirkstoffkombinationen
NO20024679L (no) Krystallinsk farmasöytikum
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater
NO20004464D0 (no) Narresmokk